Term ended May 26, 2026 · Medium confidence
20-year base term ended May 26, 2026
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 8,940,721), so the cap could be lower.
May 26, 2006
May 26, 2026
Feb 23, 2016
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 26, 2006, when application 11/441,848, the earliest non-provisional in its chain, was filed (this one was filed Dec 23, 2014) | May 26, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,973,025, US 8,940,721, US 9,814,701) | resolves to May 26, 2026, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | May 26, 2026 | Medium confidence |
This family
| US 7,973,025 | In force Jul 2028 | Jul 2028 |
| US 8,940,721 | In force no later than Jan 2027 | no later than Jan 2027 |
| US 9,265,759 | this patent May 2026 | May 2026 |
| US 9,650,342 | Term ended May 2026 | May 2026 |
| US 9,896,419 | Term ended May 2026 | May 2026 |
| US 10,202,348 | Term ended May 2026 | May 2026 |
| US 10,913,722 | Term ended Jun 2026 | Jun 2026 |
| US 11,724,987 | Term ended Aug 2026 | Aug 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 28, 2015 Reel 36504, frame 756 | Aldexa Therapeutics, Inc. | Aldeyra Therapeutics, Inc. | Change of Name |
| Dec 28, 2015 Reel 37365, frame 630 | Jordan, Thomas A.; Dowling, John E.; Chabala, John Clifford | Neuron Systems, Inc. | Assignment of Assignor's Interest |
| Dec 28, 2015 Reel 37393, frame 995 | Neuron Systems, Inc. | Neuron Systems, Inc. | Change of Address |
| Dec 28, 2015 Reel 37394, frame 30 | Neuron Systems, Inc. | Aldexa Therapeutics, Inc. | Change of Name |
| Dec 7, 2016 Reel 40589, frame 196 | Aldeyra Therapeutics, Inc. (F/K/A Aldexa Therapeutics, Inc.) | Pacific Western Bank (as Successor in Interest by Merger to Square 1 Bank) | Security Interest |
| Dec 5, 2018 Reel 47683, frame 482 | Pacific Western Bank (Successor by Merger to Square 1 Bank) | Aldeyra Therapeutics, Inc. (F/K/A Aldexa Therapeutics, Inc. F/K/A Neuron Systems, Inc.) | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 7,973,025, US 8,940,721, US 9,814,701, ends no earlier than this term, so it caps nothing.